Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial

Journal:

Nature Communications

Published:

2026-05-07

DOI:

10.1038/s41467-026-72984-7

Affiliations:

9

Authors:

30

Go to article

Institutions	Authors	Share
Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), United States of America (USA)	13.500000 13.500000	0.45
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	10.000000 10.000000	0.33
Brigham and Women's Hospital (BWH), United States of America (USA)	5.500000	0.18
Harvard University, United States of America (USA)	1.000000	0.03

Interested in Oncology and Carcinogenesis?